In his weekly clinical update, Dr. Griffin discusses the outcomes of SARS-CoV-2, influenza and respiratory syncytial virus infection in pediatric communities under the age of 18 years, the treatment of infants with the human monoclonal anti-respiratory syncytial virus antibody to prevent hospitalizations, most recent statistics on the circulation of respiratory syncytial virus, influenza virus and SARS-CoV-2 virus in the US, how the SARS-CoV-2/COVID-19 pandemic affected school attendance and child healthcare, how exposure length influenced transmission of SARS-CoV-2, how the durability of the anti-SARS-CoV-2 antibody response to protect against virus re-infection, if administration of oral antiviral therapy affected viral rebound in either the unvaccinated or vaccinated populations, as well as a reminder of the ineffectiveness of antibiotics for treating COVID-19 and the effect of vaccination on post-COVID conditions in children between 5-17 years old.

Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email

Become a patron of TWiV!

Links for this episode

• Pediatric outcomes SARS-CoV-2, flu, RSV (JAMA Peds.)
• SARS-CoV-2 vs Flu (Wired)
• Anti-RSV antibody treatment for infants (NEJM)
• Respiratory disease surveillance (CDC)
• RSV surveillance (CDC)
• RSV national trend (CDC)
• Influenza/flu surveillance (CDC)
• COVID-19 hospital admissions (CDC)
• COVID-19 national trend (CDC)
• COVID-19 wastewater testing (biobot)
• COVID-19 school attendance (JPEIDS)
• COVID-19 pandemic effects children health care (JPEIDS)
• Digitally measuring transmission (Nat)
• Antibody titers and re-infection (CMI)
• Oral antiviral and SARS-CoV-2 rebound (MMWR)
• Rebound after antiviral controlled trial (MMWR)
• Vaccination and antiviral therapy (OFID)
• Antivirals and hospitalization (JMV)
• Antivirals molnupiravir (JMV)
• Convalescent plasma and the immunocompromised guidelines (IDSOciety)
• Steroid and the cytokine storm (OFID)
• Anticoagulation guidelines (hematology.org)
• Unnecessary antibiotics (NEJM)
• Vaccination and long COVID (OFID)
• RSV vaccination (MMWR)
• Antivirals and chronic kidney disease (CID)
• Early administraton of molnupiravir versus ritonavir-boosted nirmatrelvir (Lancet)
• Contribute to our MicrobeTV fundraiser at PWB
• Letters read on TWiV 1074
• Dr. Griffin's COVID treatment summary (pdf)
• Timestamps by Jolene. Thanks!

Intro music is by Ronald Jenkees

Send your questions for Dr. Griffin to [email protected]